<?xml version="1.0" encoding="UTF-8"?>
<p>The number of patients starting each cycle was: glasdegib induction, 
 <italic>n</italic> = 69 (100.0%); re‐induction cycle 2, 
 <italic>n</italic> = 14 (20.3%); consolidation, 
 <italic>n</italic> = 26 (37.7%); and maintenance, 
 <italic>n</italic> = 15 (21.7%). Of the 15 patients who received at least 1 cycle of maintenance therapy, 6 completed 6 cycles, 6 discontinued due to cytogenetic or morphological relapse, 2 discontinued due to AEs (grade 1‐2 nausea/diarrhea; grade 3 muscle spasms) and one patient refused further treatment after receiving 11 cycles of maintenance. Following discontinuation of the study treatment, 72.5% (
 <italic>n</italic> = 50) of patients received follow‐up systemic therapies, with the majority of patients (
 <italic>n</italic> = 39) receiving chemotherapy (Supporting Information 
 <xref rid="ajh25238-supitem-0001" ref-type="supplementary-material">Table S2</xref>).
</p>
